What happened
PACS Group, Inc. (NYSE: PACS) said Jason Hulse Murray sold 118,729 shares from 2026-10-14 to 2026-10-16. Murray is identified as Co-Founder, CEO & Chairman, a director and a 10% owner. The filing shows sales across multiple transactions at prices from $45.00 to $48.11 per share. The form lists separate sales on 2026-10-14, 2026-10-15 and 2026-10-16. Those sales totaled about $5.61 million. After the sales, Murray held 54,316,520 shares.
The filing says the trades were made under a Rule 10b5-1 trading plan. The form was filed on 2026-10-16.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 118,729 shares | SEC Form 4 | |
| Sale price range | $45.00 to $48.11 per share | SEC Form 4 | |
| Total value sold | about $5.61 million | SEC Form 4 | |
| Shares held after sale | 54,316,520 shares | SEC Form 4 |
Read more: PACS Group (PACS) stock analysis and investment case
Why it matters
For investors, the filing mainly updates ownership rather than operations, but it gives a clear view of a still-large insider stake. OptimistFi's calculation puts the 118,729 shares at about 0.2% of Murray's holding before the trade. That makes the sale small relative to the 54,316,520 shares still reported after it, even though the dollar value was about $5.61 million. The remaining holding of 54,316,520 shares is still large enough that this filing reads as a position trim, not an exit.
The strongest caveat is the Rule 10b5-1 disclosure, because the filing ties the sales to a prearranged plan instead of a fresh discretionary move. OptimistFi's case is that PACS can compound if its independently operated facility model keeps turning post-acute demand into profitable cash flow despite labor, reimbursement and regulatory pressure. This filing is mixed for that view because it trims the stake, but it does not by itself challenge the operating thesis.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
The next investor checkpoint is PACS Group's next quarterly report. That report will be the next dated test of the thesis. A report with steady results would strengthen OptimistFi's case. Weaker results would weaken it. If the operating data holds up, the planned sale will look routine inside a large position. If it does not, the planned sale will sit beside the report as another reason investors may reassess the name.
More from OptimistFi
- PACS stock: the PACS Group thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Perps news: leveraged stocks, gold, FX and crypto on-chain
- Prop firms that fund crypto and stock perps traders: rules, prices and payouts
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
Sources
- SEC Form 4 — Insider sale by Jason Hulse Murray and post-trade holding in PACS Group, Inc.
Read the full OptimistFi thesis on PACS Group, Inc.: https://optimistfi.com/stocks/PACS
See what would break the PACS Group, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full PACS Group, Inc. investment case, its status and the next test to watch live on the PACS Group, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
